Prognostic role of sensitive-to-apoptosis gene expression in rectal cancer

Table 1 Clinicopathological factors and gene expression

		Survival (%)			Multivariatesignificance
	n	12 mo	24 mo	36 mo	P value
Age (yr)
< 50	10	80	80	66	0.135
> 50	21	76	57	47
Sex
Male	17	64	52	45	0.073
Female	14	92	78	62
preT
T2	1	100	100	100	0.052
T3	24	79	70	59
T4	6	66	33	16
preN
N0	18	77	66	66	0.036
N+	13	76	61	0
Grade
Low	4	100	75	75	0.0337
Moderate	22	77	68	58
High	4	50	25	0
pN
N0	17	70	64	58	0.044
N1	6	83	83	56
N2	3	66	83	67
pT
T0	6	83	66.7	66.7	0.067
T1	2	100	100	100
T2	4	75	75	75
T3	19	73	63	57
Vascular invasion
Negative	7	71	57	57	0.019
Positive	24	79	66.7	52.7
Perineural invasion
Negative	17	76.5	64.7	64.7	0.068
Positive	13	76.9	61.5	35.9
Metastasis
Negative	23	78	73	63	0.009
Positive	8	75	50	25
SAG expression
Increase	16	62	56	56	0.056
Decrease	15	93	73	49
Bak expression
Increase	14	73	62	31	0.731
Decrease	17	68	56	56
Bcl-XL expression
Increase	12	66	58	43	0.336
Decrease	19	84	68	61

Clinical features of the 31 patients who received preoperative chemoradiotherapy and a summary of the relationship between protein expression level and patient survival after 1, 2 and 3 years of follow-up. SAG: Sensitive-to-apoptosis; CRT: Chemoradiotherapy.